Marta Schirripa

7PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Carlo Signorelli, Michele Basso, Maria Alessandra Calegari

|Feb 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.

Somaieh Hedayat, Luciano Cascione, David Cunningham

|May 26, 2020
Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.

Mohamed E Salem, J Nicholas Bodor, Alberto Puccini

|Mar 12, 2019
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.

Ryuma Tokunaga, Shu Cao, Madiha Naseem

|Nov 10, 2018
Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.

Mitsukuni Suenaga, Shu Cao, Wu Zhang

|Jun 02, 2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.

Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa

Pageof 2

Frequent Collaborators

2 joint publications

Satoshi Okazaki

2 joint publications

Fotios Loupakis

1 joint publications

Mitsukuni Suenaga

1 joint publications

Yuji Miyamoto